| Titolo |
Pubblicato in |
Anno |
| Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients |
EXPERT REVIEW OF HEMATOLOGY |
2022 |
| Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents |
CURRENT CANCER DRUG TARGETS |
2022 |
| Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid
Leukemia Patients in Deep Molecular Response Preparing for Treatment
Discontinuation |
JOURNAL OF CLINICAL MEDICINE |
2022 |
| Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols |
ACTA ONCOLOGICA |
2021 |
| Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience |
LEUKEMIA & LYMPHOMA |
2021 |
| Therapeutic strategies in low and high-risk MDS: What does the future have to offer? |
BLOOD REVIEWS |
2021 |
| Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up |
LEUKEMIA & LYMPHOMA |
2021 |
| Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients |
ANNALS OF HEMATOLOGY |
2021 |
| Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA |
2021 |
| Real-life evaluation of potential candidates for treatment
discontinuation in chronic myeloid leukemia: the impact of age and
long-term follow-up |
LEUKEMIA & LYMPHOMA |
2021 |
| Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab |
ANNALS OF HEMATOLOGY |
2021 |
| Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients
with Chronic Myeloid Leukemia: A ``Campus CML{''} Study |
BLOOD |
2021 |
| Hemoglobin Changes during Long-Lasting Frontline Treatment with
Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia |
BLOOD |
2021 |
| Real-life comparison of nilotinib versus dasatinib as second-line
therapy in chronic phase chronic myeloid leukemia patients |
ANNALS OF HEMATOLOGY |
2021 |
| Clinical and Prognostic Features of Essential Thrombocythemia:
Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large
Single-center Cohort |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA |
2021 |
| Measuring prognosis in chronic myeloid leukemia: what's new? |
EXPERT REVIEW OF HEMATOLOGY |
2021 |
| Acute promyelocytic leukemia (APL) in very old patients: real-life
behind protocols |
ACTA ONCOLOGICA |
2021 |
| Long term follow-up of frontline Dasatinib in older patients with
chronic myeloid leukemia in chronic phase treated outside clinical
trials: a real-life cohort observational study |
ACTA ONCOLOGICA |
2021 |
| Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience |
ANNALS OF HEMATOLOGY |
2020 |
| The advantages and risks of ruxolitinib for the treatment of polycythemia vera |
EXPERT REVIEW OF HEMATOLOGY |
2020 |
